Comparative Pharmacology
Head-to-head clinical analysis: OXTRIPHYLLINE PEDIATRIC versus THEO DUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXTRIPHYLLINE PEDIATRIC versus THEO DUR.
OXTRIPHYLLINE PEDIATRIC vs THEO-DUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
Inhibits phosphodiesterase, increasing cAMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
300-600 mg orally twice daily
None Documented
None Documented
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Terminal elimination half-life: 3-9 hours in adults (smokers: 4-5 hours; nonsmokers: 6-9 hours); 20-30 hours in premature neonates; 1-5 hours in children. Prolonged in hepatic cirrhosis, heart failure, and with CYP1A2 inhibitors.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Primarily hepatic metabolism by CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for approximately 10% in adults, up to 50% in neonates; biliary/fecal excretion negligible.
Category C
Category C
Bronchodilator
Bronchodilator